Immune system (Dendritic cell-mediated antigen presentation)

This target refers to the complex physiological process of immune system activation triggered by influenza virus antigens, specifically Hemagglutinin (HA) and Neuraminidase (NA), in the presence of the adjuvant Azoximer bromide (Polyoxidonium). Azoximer bromide is a synthetic high-molecular-weight polymer that functions by stimulating dendritic cells, which are the primary antigen-presenting cells of the immune system (Dyakonova et al., 2018). It promotes the maturation of these cells, evidenced by the increased expression of co-stimulatory molecules such as CD80 and CD86, which are essential for the effective activation of T-lymphocytes (Panteleev et al., 2020). This enhanced antigen presentation leads to a more robust production of specific antibodies and the establishment of long-term immunological memory against influenza (Ait-Haddou et al., 2020). The mechanism is particularly valuable in vaccine development to improve the immunogenicity of subunit vaccines, especially in elderly or immunocompromised populations. While generally safe, the activation of these pathways can lead to localized inflammation or rare hypersensitivity reactions (Petrov et al., 2000).

Other names

Polyoxidonium-enhanced immune responseAzoximer bromide-enhanced dendritic cell activationAntigen presentation of influenza HA/NADendritic cell activation pathway

Azoximer bromide acts as an immunomodulatory adjuvant that enhances the migration, maturation, and antigen-presenting capacity of dendritic cells, thereby increasing the adaptive immune response to influenza hemagglutinin (HA) and neuraminidase (NA) antigens.